Table 1. Patient Characteristics and Outcome.

Subject Number	Age/Diagnosis	Transplant type/Center	Time post-SCT for CMV reactivation	Cell dose of CMV specific CTL( CD3+CMV CTL/kg)	Number of infusions	Immuno- suppression	CMV CTL response/timing	Changes in CMV DNA Levels Post- infusion over tIme
1	19 years /MDS	Haplo-TCD UCSF	4weeks	5×105	2	No	Yes/4 weeks	2000 to 100 3 weeks
2	4 years/Hyper IgM syndrome	Haplo-TCD UCSF	2 weeks	5×105	1	No	No*	persistent viremia
3	14 years/AML	MUD-unmod PSHMC	4 weeks	5×105	1	CSA/prednis one	Transient/3 weeks	2200 to 0 3 weeks
4	9 mo/SCID	Haplo-TCD UCSF	8 months	5×105	1	No	Yes/6 weeks	2054 to 0 2 weeks
5	11 years/T cell lymphoblastic lymphoma	Haplo-TCD LCH	3 weeks	2.5×105	2	Plaquenil/ Prednisone	Yes/4 weeks	Intermittent viremia post- infusion; CMV retinitis
6	2 years/CID	Haplo-TCD UCSF	1 week	2.5×105	1	No	Yes/4 weeks	1500 to 0 1 week
7	19/HLH	MUD-unmod KUMC	1 week	5×105	1	Prednisone	Transient/3 weeks	Viremia recurred after steroids used for presumed HLH

AML: acute myelogenous leukemia; MDS: myelodysplastic syndrome; HLH: Hemophagocytic lymphohistiocytosis; (S)CID: (severe) combined immunodeficiency; Haplo: human leukocyte antigen haplo-identical, related donor; MUD: matched unrelated donor; TCD: T cell depleted; unmod: unmodified bone marrow. Centers: University of California at San Francisco-UCSF; Penn State Hershey Medical Center-PSHMC; Levine Children’s Hospital-LCH; University of Kansas Medical Center-KUMC.